<DOC>
	<DOC>NCT00345059</DOC>
	<brief_summary>The purpose of this study is to compare the overall survival of patients with advanced non small cell lung cancer treated with docetaxel as single therapy versus docetaxel in combination with either gemcitabine or vinorelbine or in combination with capecitabine.</brief_summary>
	<brief_title>The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer</brief_title>
	<detailed_description>This study is for patients with previously diagnosed advanced non small cell lung cancer (NSCLC, stage IIIb or IV) who had progression of their disease during or after first-line therapy containing platinum. Patients will be assigned to receive 6 cycles of therapy from one of four treatment regimens: - docetaxel - docetaxel + vinorelbine - docetaxel + gemcitabine - docetaxel + capecitabine</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<criteria>Written informed consent Age &gt; 18 Histological diagnosis of non smallcell lung cancer (NSCLC) Stage IIIb or Stage IV disease (in IIIb, previous treatment with chemotherapy + radiotherapy, or metastatic supraclavicular lymph nodes or pleural effusion) Disease in progression Previous chemotherapy with platinumderivative (and with &gt; 21 days from last administration) ECOG performance status &gt; 2 Age &gt; 75 years History of malignant neoplasm within the previous 5 years (except for baso or spinocellular skin carcinoma and insitu carcinoma of the uterine cervix, provided they are being adequately treated) Previous treatment with docetaxel Presence of symptomatic cerebral metastasis Neutrophils &lt; 2.0 x 109/l, platelets &lt; 100,000/l, hemoglobin &gt; 10g/dl Bilirubin &lt; 1.5 x the upper normal limit SGOT , SGPT, or bilirubin &gt; 1.25 x the upper normal limits except in the presence of hepatic metastasis Creatinine &gt;1.25 x the upper normal limit Any concomitant pathology that would, in the Investigator's opinion, contraindicate the use of the drugs in the protocol Inability to comply with follow up Pregnant or nursing females</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>second line</keyword>
	<keyword>monochemotherapy</keyword>
	<keyword>combination chemotherapy</keyword>
	<keyword>platinum refractory</keyword>
	<keyword>previously treated</keyword>
</DOC>